A Randomized Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Bivalent RSVpreF Vaccine in Older Adults in Korea
Won Suk Choi, Karen Quan, James A. Baber, Anna Jaques, Karla Janse van Rensburg, Wen Li, Mark W. Cutler, Elena V. Kalinina, Annaliesa S. Anderson, Kena A. Swanson, Alejandra Gurtman, Iona Munjal · 2026
Read A Randomized Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Bivalent RSVpreF Vaccine in Older Adults in Korea by Won Suk Choi, Karen Quan, James A. Baber, Anna Jaques, Karla Janse van Rensburg, Wen Li, Mark W. Cutler, Elena V. Kalinina, Annaliesa S. Anderson, Kena A. Swanson, Alejandra Gurtman, Iona Munjal (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13611546.txt.
Description
A vaccine against RSV, a lung virus that endangers older adults, needs safety proof in each new population. Won Suk Choi and co-authors run that proof in Korea in a 2026 trial. They enroll 377 adults aged sixty and up.
Two thirds got the vaccine and one third a placebo shot. Sore arms led the local effects, at 12.4 percent in the vaccine arm. Tiredness and muscle ache were the top body-wide effects. Few ill events followed, and none were blamed on the vaccine. Antibody levels jumped about ninefold for both virus types. The profile matches the vaccine's big global trials.
Catalog record
| CREATOR | Won Suk Choi, Karen Quan, James A. Baber, Anna Jaques, Karla Janse van Rensburg, Wen Li, Mark W. Cutler, Elena V. Kalinina, Annaliesa S. Anderson, Kena A. Swanson, Alejandra Gurtman, Iona Munjal |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |